Top Banner
Evaluation of Dyspnea
43

Evaluation of Dyspnea

Jan 08, 2016

Download

Documents

huyen

Evaluation of Dyspnea. Variable Definitions Of Dyspnea. Unpleasant or uncomfortable respiratory sensations Difficult, labored, uncomfortable breathing Awareness of respiratory distress The sensation of feeling breathless or air hunger An uncomfortable sensation of breathing - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Evaluation of Dyspnea

Evaluation of Dyspnea

Page 2: Evaluation of Dyspnea

Variable Definitions Of Dyspnea

• Unpleasant or uncomfortable respiratory sensations • Difficult, labored, uncomfortable breathing• Awareness of respiratory distress• The sensation of feeling breathless or air hunger• An uncomfortable sensation of breathing

• ATS guidelines: subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity

ATS. AJRCCM, 1999.

Page 3: Evaluation of Dyspnea

Variation In Symptoms of Dyspnea by Condition

Manning. NEJM, 1995.

Page 4: Evaluation of Dyspnea

Respiratory Control Systems

• Designed to maintain gas exchange equilibrium and acid base status

• Abnormalities in this system -> dyspnea-> severe patient distress

Page 5: Evaluation of Dyspnea

Mechanisms Of Dyspnea: Respiratory Center Output

• Chemoreceptors– Peripheral: carotid

bodies, aortic arch • Sense changes in PO2,

acidosis, hypercapnea– Central: medulla

• pH and PCO2 changes• Hypercapnea

– Potent stimulus of dyspnea

• Hypoxia– Less potent stimulus

than hypercapnea

Manning. NEJM, 1995.

Page 6: Evaluation of Dyspnea

Mechanisms Of Dyspnea: Stimulation Of Mechanoreceptors

• Mechanoreceptors– Upper airway– Pulmonary receptors

• Limitations of movement exacerbate dyspnea

• The sensation of dyspnea varies with activation

– Chest wall receptors• Restricted motion

exacerbates dyspnea• Redundant to pulmonary

receptors

Nausherwan. Chest, 2010.

Page 7: Evaluation of Dyspnea

Other Mechanisms Of Dyspnea

• Mechanical loading– Changes in airway resistance, pulmonary or chest wall

compliance• Neuromechanical dissociation

– Air flow not equal to expected results of brain output• Impaired oxygen utilization or delivery

– Anemia• Increased CO -> EDP-> pulmonary edema• Localized acidosis or resp muscle fatigue

– Deconditioning• Poor cardiac and peripheral efficiency, early anaerobic metabolism

and acidosis

Page 8: Evaluation of Dyspnea

Structural Approach

• Respiratory– Controller: depth and rate of breathing– Ventillatory pump: movement of gas in and out of

the alveolous– Gas exchanger: pulmonary vasculature, alveoli

• Cardiac– Anemia– Deconditioning– Heart failure

Page 9: Evaluation of Dyspnea

Most Common Causes of Dyspnea

• Asthma• COPD• ILD• Cardiac disease

Page 10: Evaluation of Dyspnea

Differential Diagnosis of Dyspnea

• Cardiac– Heart failure– Coronary artery disease– Arrhythmia– Pericardial disease– Valvular heart disease– Pulmonary hypertension

Page 11: Evaluation of Dyspnea

Diagnosis of Dyspnea

• Pulmonary– Chronis obstructive pulmonary disease– Asthma– Interstitial lung disease– Pleural effusion– Malignancy– Bronchiectasis

Page 12: Evaluation of Dyspnea

Diagnosis of Dyspnea• Non-cardiac/Non-pulmonary

– Thromboembolic disease– Psychogenic– Deconditioning – Obesity– Anemia– GERD– Metabolic conditions– Cirrhosis– Thyroid disease– Neuromuscular – Chest wall– Upper airway

Page 13: Evaluation of Dyspnea

Approach To The Patient

• History and physical• EKG• Echocardiogram• CXR/CT scan• Spirometry• Cardiopulmonary exercise testing

Page 14: Evaluation of Dyspnea

Differentiating Heart vs Lung Etiology

• 1586 patients presenting with dyspnea

• No clear heart failure

Maisel. NEJM, 2002.

Page 15: Evaluation of Dyspnea

BNP Is Useful to Differentiate Heart Failure From Other Dyspnea

Maisel. NEJM, 2002.

Page 16: Evaluation of Dyspnea

Case 1

• A 30 year old woman presents with progressive exercise tolerance for the last 3 months. She ran a marathon at age 26, but now has shortness of breath walking up 1 flight of stairs. She denies chest pain, orthopnea or PND but has intermittent mild ankle edema.

Page 17: Evaluation of Dyspnea

Case1

• Her blood pressure is normal and her exam is unremarkable. Her EKG and CXR are shown. What test should be ordered next?– A treadmill stress test– Pulmonary function testing– A blood test for BNP– A CT scan of the chest– An echocardiogram

Page 18: Evaluation of Dyspnea

Electrocardiogram

Page 19: Evaluation of Dyspnea

Chest XR

Page 20: Evaluation of Dyspnea

Case 1

• What test should be ordered next?– A treadmill stress test– Pulmonary function testing– A blood test for BNP– A CT scan of the chest– An echocardiogram

Page 21: Evaluation of Dyspnea

Case 1

• An echocardiogram is performed.

Page 22: Evaluation of Dyspnea

Echocardiogram

Page 23: Evaluation of Dyspnea

Case 1

• The next best step is to:– Start sildenafil 20 mg TID– Send the patient for a right heart catheterization– Send tests for rheumatologic disease– Start an ACE Inhibitor

Page 24: Evaluation of Dyspnea

Hemodynamics

RA (mmHg) 9

PA (mmHg) 92/44 (65)

PCWP (mmHg) 7

CO (L/min) 3

PVR (Wood Units)

19

Page 25: Evaluation of Dyspnea

Right Sided Heart Failure

• Most commonly associated with left sided heart failure

• Pulmonary hypertension is another common cause

Page 26: Evaluation of Dyspnea

Patients Die From Right Heart Failure

www.clarian.org/ADAM/doc/HealthIllustratedEncyclopedia/2/18131.htmwww.mdconsult.com/das/patient/body/196982233-3/0/10041/35062.html

Page 27: Evaluation of Dyspnea

WHO Classification of PH

I. Pulmonary arterial hypertension

1. Idiopathic2. Heritable3. Drug/toxin induced4. Associated (HIV, CTD,

CHD, schistosomiasis)I . ′ PVOD, PCHII. PH from left heart

disease1. Systolic dysfunction2. Diastolic dysfunction 3. Valvular disease

III. PH from lung disease or hypoxemia

1. ILD2. COPD3. OSA4. Altitude

IV. CTEPHV. Multifactorial

1. Hematologic2. Systemic (sarcoid,

vasculitis)3. Metabolic (glycogen

storage)4. Other (tumor)

Page 28: Evaluation of Dyspnea

Localization of Abnormalities

Dijke. Nature Reviews Molecular and Cell Biology. 2007.University of Michigan website

Page 29: Evaluation of Dyspnea

Progression of PAH

PAP

PVR

CO

Time

Pre-symptomatic/ Compensated

Symptomatic/ Decompensating

Symptom Threshold

Right Heart Dysfunction

Declining/ Decompensated

CO =PAP

PVR

Page 30: Evaluation of Dyspnea

Humbert. NEJM, 2004.

Targets for Therapies in Pulmonary Arterial Hypertension

Page 31: Evaluation of Dyspnea

Acute Pulmonary Embolism

Page 32: Evaluation of Dyspnea

Case 2

• A 68 year old HTN, diabetic female presents with progressive shortness of breath over the last 5 years. She can walk about 2 blocks before needing to rest.

Page 33: Evaluation of Dyspnea

Case 2

• The examination shows tachycardia and a normal blood pressure. There are bibasilar crackles and an S3 on exam.

Page 34: Evaluation of Dyspnea

EKG

Page 35: Evaluation of Dyspnea
Page 36: Evaluation of Dyspnea

Case 2

• There was trace LE edema. The EKG shows LVH. An echocardiogram shows LVH and severe diastolic dysfunction.

Page 37: Evaluation of Dyspnea

Case 2

• The next best step is:– A nuclear stress test– Aggressive blood pressure management– A coronary angiogram– Aggressive management of diabetes

Page 38: Evaluation of Dyspnea

Diastolic Heart Failure

• Nearly ½ of all patients with heart failure

• 65% 5 year mortality

Shah. JAMA, 2008.

Page 39: Evaluation of Dyspnea

Typical Features Of Patients With Diastolic Heart Failure

• Female: 62-66%• Elderly: mean age 72-74• Comorbidities

– CAD 36-53%– HTN 55-77%– AF 32-41%– DM 32-45%– CKD 23-26%– Obesity– Anemia

Page 40: Evaluation of Dyspnea

Mortality In Diastolic Heart Failure Is High

Owan. NEJM, 2006.

Page 41: Evaluation of Dyspnea

Diastolic Heart Failure: Elevated LV Filing Pressures

Nagueh. JASE, 2009.

Page 42: Evaluation of Dyspnea

What Does DHF Look Like On Echo?

Nagueh. JASE, 2009.

Page 43: Evaluation of Dyspnea

Treatment

• Treatment of comorbidities